PETER GOODFELLOW, DPHIL
Chair of the Board
Peter Goodfellow is a Senior Science Advisor for Abingworth. Peter was previously the Balfour Professor of Genetics at the University of Cambridge before working for SmithKline Beecham (later GSK) as Head of Research. He has founded several biotechnology companies and has sat on the Boards of Prosensa, deCode, , GenSight Biologics, and various medical charities and is also currently Chair of GammaDelta Therapeutics.
Peter holds doctorates from the Universities of Oxford and Bristol. He is also a Fellow of the European Molecular Biology Organisation (EMBO), the Academy of Medical Sciences, and the Royal Society.
NATALIE MOUNT, PHD
Chief Executive Officer
Natalie is an experienced leader and innovator with a 25 year track record in drug discovery and development roles. Natalie was part of the founding management team at GammaDelta Therapeutics where she served as Chief Scientific Officer from its establishment until 2019. Previously she was part of the founding management team at the Cell and Gene Therapy Catapult as Chief Clinical Officer. Her experience also includes 16 years at Pfizer Research and Development working on different modalities across a range of therapeutic areas. Natalie has also held Independent Director positions on the Boards of biotech companies, including GenSight Biologics and Rinri Therapeutics.
Natalie holds a first class degree in Natural Sciences from University of Cambridge and a PhD from University College, London.
Tim Haines is Chairman and Managing Partner at Abingworth, and has more than 30 years of international management experience in the life sciences industry at both public and private companies. During his time at Abingworth, Tim has taken Chairman and Board roles in a number of companies including Astex, Fovea, GammaDelta Therapeutics, MEDIAN, PixiumVision, PowderMed, Sientra, and Stanmore.
Before joining Abingworth in 2005, he was the Chief Executive Officer of the Abingworth portfolio company, Astex Therapeutics. At Astex Tim was instrumental in establishing it as one of the leading UK biotechnology companies. Previously, he was Chief Executive of two divisions of the publicly-listed medical technology company, Datascope. Prior to this, he held a number of other senior management positions in the US and Europe, including as Chief Executive Officer of Thackray, and as General Manager of Baxter UK.
Tim has a BSc from Exeter University and an MBA from INSEAD.
DAN KEMP, PHD
Dr. Dan Kemp is Vice President, Head of Cell Therapies Business Development & Operations at Takeda Pharmaceuticals, leading R&D collaboration deals and transactions primarily in the oncology space. Previously, he was Senior Vice President at Beryllium, and responsible for directing drug discovery partnerships. Dan ran programmes from target validation through to clinical proof of concept at Merck Research Laboratories, and prior to that led a team at Novartis Institutes for BioMedical Research developing innovative concepts for metabolic diseases.
Dan has authored over 30 papers or book chapters, of which 24 are original research contributions. Dan received a BSc and PhD in 2000 from the University of Kent at Canterbury; he was later awarded an HHMI Research Fellowship at Harvard Medical School, where he carried out post-doctoral research.
LOIC VINCENT, PHD
Based at Takeda’s Cambridge, MA, Research campus, Loïc is leading the Oncology Drug Discovery Unit and the Immunology Unit. Loïc is also a member of the Research Senior Leadership Team at Takeda. Together with his team, Loïc built the Oncology Research portfolio (mainly Immuno-Oncology) with a global network of world class biotech and academic collaborators.
Prior to joining Takeda in 2016, Loïc spent 9 years at Sanofi, where he led Oncology Drug Discovery Pharmacology, Immuno-Oncology and Oncology External Innovation teams. Prior to joining Sanofi in 2007, Loïc was the Head of Pharmacology and Oncology programs at Endotis Pharma.
An Oncology Scientist with international academia/biotech/pharma industry experience, Loïc obtained his Ph.D. in Pharmacology from the University of Rouen, France and received the Young Scientist Award from the Bettencourt-Schueller’s Foundation for his work. Loïc carried out his postdoctoral fellowship in Oncology at the Weill Medical College of Cornell University, NY.
Loïc is a board member of the French-American Biotechnology Springboard.
JOHN SHIELDS, PHD
John Shields is an independent director who has extensive operational and investment experience in the biotechnology sector. He serves on a number of biotechnology company boards and company science advisory boards. In addition, he is currently a member of the Sanger Institute Translation Committee, the Crick Institute Translation Advisory Group, the Cancer Research UK CoLC SAB, the Biomedical Catalyst Major Awards Committee and the MRC’s Translational Research Group.
Previously John was an employee of Abingworth LLP, the life-sciences focused venture capital group, and has also worked in the pharma and biotech industry, initially at Glaxo and then as SVP Research for Cantab Pharmaceuticals. John has a PhD in Immunology from the University of Glasgow.